


| [Articles] Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial |
|
SELECT-AXIS 1 is a multicentre, randomised, double-blind, parallel-group, placebo-controlled, phase 2/3, two-period study of upadacitinib ( appendix p 3 ). Patients were enrolled from 62 sites in 20 countries (in North America, eastern and western Europe, Asia, and Oceania; appendix p 2 ).
Posted: 2019-12-06 00:42:00
|
If you are a broadcaster or Christian program producer you can schedule a 15 min FREE consultation with an EGR specialist to help you evaluate all possible Int'l broadcasting options.
We will call you back at a number and time of your convenience, and will gladly answer any question that you may have on how to broadcast your Christian message worldwide.